Source comparison
Tesamorelin + Ipamorelin Blend Anti-Aging Complete Guide 2026: Peptide Blend Comparison
Before selecting a peptide protocol, understanding how tesamorelin + ipamorelin compares to alternative GH-modulating compounds clarifies why this specific blend has become the research standard in 2026. | Peptide or Blend | Primary Mechanism | Visceral Fat Re
This comparison does not assign a generated winner or score.
- Before selecting a peptide protocol, understanding how tesamorelin + ipamorelin compares to alternative GH-modulating compounds clarifies why this specific blend has become the research standard in 2026.
- | Peptide or Blend | Primary Mechanism | Visceral Fat Reduction | GH Pulse Amplitude | Cortisol/Prolactin Elevation | Administration Frequency | Professional Assessment ||—|—|—|—|—|—|| Tesamorelin + Ipamorelin (1mg:200mcg) | Dual pathway: GHRH agonist + ghrelin mimetic with somatostatin suppression | 15–18% reduction over 26 weeks (HIV lipodystrophy data) | 140–240% vs monotherapy | None (selective GHS-R1a agonism) | Nightly subcutaneous | Gold standard for visceral adiposity and age-related GH decline. Synergistic mechanism with minimal off-target effects || CJC-1295 + Ipamorelin | GHRH analogue with extended half-life + ghrelin mimetic | Moderate (10–14% over 24 weeks) | 120–180% vs baseline | None | 2–3× weekly subcutaneous | Extended pulsatile release. Preferred when injection frequency is a limiting factor, but lower visceral fat specificity than tesamorelin || Tesamorelin Monotherapy | GHRH receptor agonist | 15–18% (validated in EGRIFTA trials) | Baseline to moderate | None | Ni
- The tesamorelin + ipamorelin blend delivers visceral fat reduction on par with tesamorelin monotherapy while achieving GH pulse amplitudes that neither peptide produces alone. Without the cortisol elevation, water retention, or glucose dysregulation seen with older-generation secretagogues.